Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Optimizing Tissue Biopsy and Disease Staging in Early-Stage NSCLC

April 16th 2025

Panelists discuss how medical professionals frequently encounter tissue adequacy challenges in comprehensive genomic profiling for early-stage non–small cell lung cancer (NSCLC), employing strategies such as optimized biopsy techniques, efficient tissue triage protocols, and complementary liquid biopsies to ensure sufficient material for complete molecular analysis.

CCTG BR.31 Data Show Adjuvant Durvalumab Does Not Alter Relapse Frequency or Patterns in Resected NSCLC

April 16th 2025

Adjuvant durvalumab was not associated with a reduction in the frequency of relapse in NSCLC.

Comprehensive Molecular Testing in Early-Stage NSCLC: Best Practices and Multidisciplinary Strategies

April 16th 2025

Panelists discuss how medical professionals currently approach molecular testing in early-stage non–small cell lung cancer (NSCLC) through comprehensive biomarker analysis, including targeted next-generation sequencing (NGS), to identify actionable mutations that guide adjuvant therapy decisions and improve patient outcomes.

Enhanced Dermatologic AE Prophylaxis Is Effective in EGFR-Mutated Advanced NSCLC

April 15th 2025

Enhanced dermatologic management lowered rates of dermatologic AEs during first-line amivantamab/lazertinib treatment for EGFR-mutated advanced NSCLC.

Dr Abu Rous on the Identification of Clinically Actionable Biomarkers in Squamous Cell Carcinoma of the Lung

April 14th 2025

Fawzi F Abu Rous, MD, discusses the need for reliable predictive biomarkers for therapeutic development in squamous cell carcinoma of the lung.

The OncFive: Top Oncology Articles for the Week of 4/6

April 12th 2025

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

Dr Saxena on the Evolving Utility of Targeted Therapies for ALK+ NSCLC

April 11th 2025

Ashish Saxena, MD, PhD, discusses the evolving utility of targeted therapies for ALK-positive non–small cell lung cancer.

Tarlatamab Yields OS Improvement in SCLC After Platinum Progression

April 11th 2025

Tarlatamab improved overall survival vs chemotherapy in small cell lung cancer following progression on or after platinum-based chemotherapy.

Health Canada Approves Durvalumab Monotherapy for Limited-Stage Small Cell Lung Cancer

April 11th 2025

Durvalumab received approval from Health Canada for patients with LS-SCLC whose disease has not progressed after platinum-based chemoradiation.

Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration

April 10th 2025

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

April 10th 2025

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Osimertinib Plus Dato-DXd Shows Efficacy in Post-Osimertinib EGFR-Mutated Advanced NSCLC

April 9th 2025

Osimertinib plus Dato-DXd elicits responses in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib.

Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in Metastatic NSCLC

April 9th 2025

Subcutaneous and intravenous pembrolizumab provided comparable efficacy and safety in patients with previously untreated, metastatic non–small cell lung cancer.

Daraxonrasib Generates Clinical Activity With Manageable Safety in RAS-Mutant NSCLC

April 8th 2025

Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.

Savolitinib Plus Osimertinib Elicits Durable Responses in Pretreated EGFR-Mutated, MET+ Advanced NSCLC

April 7th 2025

Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.

Subcutaneous Amivantamab Wins EU Approval in Multiple EGFR+ Advanced NSCLC Indications

April 7th 2025

The European Commission has approved subcutaneous amivantamab in multiple indications in advanced EGFR-mutant non–small cell lung cancer.

Future Treatment Options in EGFR-Mutant NSCLC

April 7th 2025

Panelists discuss how emerging therapies like patritumab (a HER3-directed antibody-drug conjugate [ADC]), datopotamab (a TROP2 ADC), and ivonescimab (a PD-1/VEGF bispecific) show distinct toxicity profiles compared with existing treatments, potentially influencing earlier use. Balancing efficacy gains against toxicity risks remains critical in optimizing EGFR-mutated non–small cell lung cancer (NSCLC) treatment.

Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC

April 7th 2025

Panelists discuss how various strategies have been developed to enhance the tolerability of intravenous amivantamab, including premedication, step-up dosing, and infusion rate adjustments. Adoption into clinical practice varies, with many institutions integrating these approaches to mitigate infusion-related reactions and improve patient outcomes.

Q2 2025: 7 FDA Decisions to Watch in the Realm of Oncology

April 5th 2025

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Dr Herzberg on the Distinctions Between Sotorasib and Adagrasib for KRAS G12C+ NSCLC

April 4th 2025

Benjamin Herzberg, MD the clinical similarities and key distinctions between sotorasib and adagrasib for KRAS G12C+ NSCLC.